Perrigo mentioned cautiously at JPMorgan JP Morgan said shares of Perrigo are moving higher on speculation regarding the impact from the FDA panel increasing OTC drugs. The firm said this will not be a big positive as the pharmacist will still dispense the drug in a restricted access market, and it might not even be the store brand.
Perrigo would be good acquisition for Teva, says RBC Capital RBC Capital views Perrigo (PRGO) as an attractive acquisition target and says in a note to investors that it thinks a takeover could be a good strategic fit with solid accretion for Teva (TEVA). Teva has interest in over-the-counter products and its growth rate would be boosted by the merger, RBC believes. The firm assumes a $200 per share value for Perrigo in its acquisition assumptions. Shares of the over-the-counter and generic pharmaceuticals company closed yesterday at $153.77.